FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366992707> ?p ?o ?g. }

• W4366992707 endingPage "1809" @default.
• W4366992707 startingPage "1798" @default.
• W4366992707 abstract "Chronic limb-threatening ischaemia is the severest manifestation of peripheral arterial disease and presents with ischaemic pain at rest or tissue loss (ulceration, gangrene, or both), or both. We compared the effectiveness of a vein bypass first with a best endovascular treatment first revascularisation strategy in terms of preventing major amputation and death in patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion.Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL)-2 was an open-label, pragmatic, multicentre, phase 3, randomised trial done at 41 vascular surgery units in the UK (n=39), Sweden (n=1), and Denmark (n=1). Eligible patients were those who presented to hospital-based vascular surgery units with chronic limb-threatening ischaemia due to atherosclerotic disease and who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion. Participants were randomly assigned (1:1) to receive either vein bypass (vein bypass group) or best endovascular treatment (best endovascular treatment group) as their first revascularisation procedure through a secure online randomisation system. Participants were excluded if they had ischaemic pain or tissue loss considered not to be primarily due to atherosclerotic peripheral artery disease. Most vein bypasses used the great saphenous vein and originated from the common or superficial femoral arteries. Most endovascular interventions comprised plain balloon angioplasty with selective use of plain or drug eluting stents. Participants were followed up for a minimum of 2 years. Data were collected locally at participating centres. In England, Wales, and Sweden, centralised databases were used to collect information on amputations and deaths. Data were analysed centrally at the Birmingham Clinical Trials Unit. The primary outcome was amputation-free survival defined as time to first major (above the ankle) amputation or death from any cause measured in the intention-to-treat population. Safety was assessed by monitoring serious adverse events up to 30-days after first revascularisation. The trial is registered with the ISRCTN registry, ISRCTN27728689.Between July 22, 2014, and Nov 30, 2020, 345 participants (65 [19%] women and 280 [81%] men; median age 72·5 years [62·7-79·3]) with chronic limb-threatening ischaemia were enrolled in the trial and randomly assigned: 172 (50%) to the vein bypass group and 173 (50%) to the best endovascular treatment group. Major amputation or death occurred in 108 (63%) of 172 patients in the vein bypass group and 92 (53%) of 173 patients in the best endovascular treatment group (adjusted hazard ratio [HR] 1·35 [95% CI 1·02-1·80]; p=0·037). 91 (53%) of 172 patients in the vein bypass group and 77 (45%) of 173 patients in the best endovascular treatment group died (adjusted HR 1·37 [95% CI 1·00-1·87]). In both groups the most common causes of morbidity and death, including that occurring within 30 days of their first revascularisation, were cardiovascular (61 deaths in the vein bypass group and 49 in the best endovascular treatment group) and respiratory events (25 deaths in the vein bypass group and 23 in the best endovascular treatment group; number of cardiovascular and respiratory deaths were not mutually exclusive).In the BASIL-2 trial, a best endovascular treatment first revascularisation strategy was associated with a better amputation-free survival, which was largely driven by fewer deaths in the best endovascular treatment group. These data suggest that more patients with chronic limb-threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion should be considered for a best endovascular treatment first revascularisation strategy.UK National Institute of Health Research Health Technology Programme." @default.
• W4366992707 created "2023-04-27" @default.
• W4366992707 creator A5001444616 @default.
• W4366992707 creator A5006750448 @default.
• W4366992707 creator A5011404979 @default.
• W4366992707 creator A5012637147 @default.
• W4366992707 creator A5017661377 @default.
• W4366992707 creator A5019583656 @default.
• W4366992707 creator A5025023179 @default.
• W4366992707 creator A5025220496 @default.
• W4366992707 creator A5027132104 @default.
• W4366992707 creator A5027703697 @default.
• W4366992707 creator A5030031942 @default.
• W4366992707 creator A5035738897 @default.
• W4366992707 creator A5037192572 @default.
• W4366992707 creator A5046161371 @default.
• W4366992707 creator A5047883586 @default.
• W4366992707 creator A5050212900 @default.
• W4366992707 creator A5054444762 @default.
• W4366992707 creator A5055258456 @default.
• W4366992707 creator A5059204676 @default.
• W4366992707 creator A5074496581 @default.
• W4366992707 creator A5078764257 @default.
• W4366992707 creator A5083705353 @default.
• W4366992707 creator A5091390414 @default.
• W4366992707 date "2023-05-01" @default.
• W4366992707 modified "2023-10-09" @default.
• W4366992707 title "A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial" @default.
• W4366992707 cites W2013256551 @default.
• W4366992707 cites W2083736263 @default.
• W4366992707 cites W2112346926 @default.
• W4366992707 cites W2147924311 @default.
• W4366992707 cites W2148325862 @default.
• W4366992707 cites W2185467918 @default.
• W4366992707 cites W2226336146 @default.
• W4366992707 cites W2272599847 @default.
• W4366992707 cites W2521177852 @default.
• W4366992707 cites W2623410321 @default.
• W4366992707 cites W2795231935 @default.
• W4366992707 cites W2803682461 @default.
• W4366992707 cites W2947763482 @default.
• W4366992707 cites W2959853492 @default.
• W4366992707 cites W2973414034 @default.
• W4366992707 cites W2975859535 @default.
• W4366992707 cites W2991105043 @default.
• W4366992707 cites W2991533000 @default.
• W4366992707 cites W3045130308 @default.
• W4366992707 cites W3048019436 @default.
• W4366992707 cites W3048261935 @default.
• W4366992707 cites W3153522840 @default.
• W4366992707 cites W3196498114 @default.
• W4366992707 cites W4230304524 @default.
• W4366992707 cites W4239553742 @default.
• W4366992707 cites W4281714560 @default.
• W4366992707 cites W4290704093 @default.
• W4366992707 cites W4297067663 @default.
• W4366992707 cites W4308366161 @default.
• W4366992707 doi "https://doi.org/10.1016/s0140-6736(23)00462-2" @default.
• W4366992707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37116524" @default.
• W4366992707 hasPublicationYear "2023" @default.
• W4366992707 type Work @default.
• W4366992707 citedByCount "23" @default.
• W4366992707 countsByYear W43669927072023 @default.
• W4366992707 crossrefType "journal-article" @default.
• W4366992707 hasAuthorship W4366992707A5001444616 @default.
• W4366992707 hasAuthorship W4366992707A5006750448 @default.
• W4366992707 hasAuthorship W4366992707A5011404979 @default.
• W4366992707 hasAuthorship W4366992707A5012637147 @default.
• W4366992707 hasAuthorship W4366992707A5017661377 @default.
• W4366992707 hasAuthorship W4366992707A5019583656 @default.
• W4366992707 hasAuthorship W4366992707A5025023179 @default.
• W4366992707 hasAuthorship W4366992707A5025220496 @default.
• W4366992707 hasAuthorship W4366992707A5027132104 @default.
• W4366992707 hasAuthorship W4366992707A5027703697 @default.
• W4366992707 hasAuthorship W4366992707A5030031942 @default.
• W4366992707 hasAuthorship W4366992707A5035738897 @default.
• W4366992707 hasAuthorship W4366992707A5037192572 @default.
• W4366992707 hasAuthorship W4366992707A5046161371 @default.
• W4366992707 hasAuthorship W4366992707A5047883586 @default.
• W4366992707 hasAuthorship W4366992707A5050212900 @default.
• W4366992707 hasAuthorship W4366992707A5054444762 @default.
• W4366992707 hasAuthorship W4366992707A5055258456 @default.
• W4366992707 hasAuthorship W4366992707A5059204676 @default.
• W4366992707 hasAuthorship W4366992707A5074496581 @default.
• W4366992707 hasAuthorship W4366992707A5078764257 @default.
• W4366992707 hasAuthorship W4366992707A5083705353 @default.
• W4366992707 hasAuthorship W4366992707A5091390414 @default.
• W4366992707 hasBestOaLocation W43669927071 @default.
• W4366992707 hasConcept C126322002 @default.
• W4366992707 hasConcept C126838900 @default.
• W4366992707 hasConcept C139059822 @default.
• W4366992707 hasConcept C141071460 @default.
• W4366992707 hasConcept C2776204877 @default.
• W4366992707 hasConcept C2776626339 @default.
• W4366992707 hasConcept C2776820930 @default.
• W4366992707 hasConcept C2777202286 @default.
• W4366992707 hasConcept C2777303625 @default.
• W4366992707 hasConcept C2777466421 @default.

• next